Quantbot Technologies LP Takes Position in Edwards Lifesciences Co. (NYSE:EW)

Quantbot Technologies LP purchased a new position in Edwards Lifesciences Co. (NYSE:EW) during the 3rd quarter, Holdings Channel.com reports. The firm purchased 206,625 shares of the medical research company’s stock, valued at approximately $13,635,000. Edwards Lifesciences makes up about 0.5% of Quantbot Technologies LP’s holdings, making the stock its 10th biggest position.

A number of other institutional investors have also recently modified their holdings of EW. Bank of New York Mellon Corp boosted its stake in Edwards Lifesciences by 4.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after purchasing an additional 809,605 shares during the last quarter. Fisher Asset Management LLC increased its holdings in Edwards Lifesciences by 9.8% in the 3rd quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock worth $599,078,000 after buying an additional 806,705 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Edwards Lifesciences by 1.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,659,102 shares of the medical research company’s stock worth $241,464,000 after buying an additional 53,181 shares during the last quarter. AustralianSuper Pty Ltd lifted its stake in Edwards Lifesciences by 17.8% during the 3rd quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock valued at $216,013,000 after acquiring an additional 494,604 shares during the period. Finally, Champlain Investment Partners LLC boosted its holdings in shares of Edwards Lifesciences by 4.5% during the 3rd quarter. Champlain Investment Partners LLC now owns 3,080,703 shares of the medical research company’s stock valued at $203,296,000 after acquiring an additional 132,515 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on EW shares. Royal Bank of Canada dropped their target price on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Wolfe Research raised Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Jefferies Financial Group cut Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Finally, Barclays lowered their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Seventeen analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Trading Up 1.1 %

EW stock opened at $71.26 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The business has a 50 day simple moving average of $67.74 and a two-hundred day simple moving average of $75.48. The company has a market capitalization of $42.03 billion, a price-to-earnings ratio of 10.28, a PEG ratio of 3.96 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.59 earnings per share. Research analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Insider Activity

In related news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,262,521.36. This trade represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,000 shares of company stock worth $2,657,000 over the last 90 days. Corporate insiders own 1.27% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.